Bugworks Research
Bugworks Research Inc. (Bugworks) is a clinical-stage biopharmaceutical company that is developing novel multi-target therapeutic assets in the anti-infectives and oncology areas by integrating the latest innovations in computational biology, pharmacology, structural-biology, and medicinal chemistry. BWC0977 is currently in a Phase I clinical trial and is targeted to address unmet needs of serious hospital & community infections, and bacterial biothreats.…
Bugworks Research: Funding Rounds
| Date | Round | Amount | Investors | Source |
|---|---|---|---|---|
| 9 Feb 2022 | Series B1 | $18 Mn | Lightrock India 3one4 Capital Acquipharma Holdings Featherlite Group Global Brain Corporation I.M Holdings Jim O'Neill Kiran Mazumdar-Shaw University of Tokyo Edge Capital (UTEC) | source |
| 23 Apr 2020 | Series B | $7.5 Mn | Global Brain Corporation University of Tokyo Edge Capital (UTEC) Acquipharma Holdings | source |
| 14 Aug 2018 | Series A | $9 Mn | University of Tokyo Edge Capital (UTEC) 3one4 Capital Acquipharma Holdings | source |
Recent Signals
-
21 Jul 2025 · ma-strategic
GARDP and Bugworks expand partnership to develop oral formulation of BWC0977 source -
11 Jun 2024 · funding
GARDP to provide up to $20M to Bugworks under collaboration agreement to co-develop BWC0977 source -
27 Jul 2023 · ma-strategic
GARDP and Bugworks join forces to accelerate development of novel antibiotic BWC0977 source -
22 Feb 2023 · org-team
Bugworks Research welcomes Dr. Renu Swarup, former DBT Secretary, to its Global Advisory Board source -
19 Sep 2022 · ma-strategic
Bugworks Research Inc. and Cytecare Cancer Hospitals launch immuno-oncology research collaboration source -
9 Jun 2022 · ma-strategic
GARDP and Bugworks collaborate on cardiac safety study of antibiotic candidate BWC0977 source
News on Bugworks Research
No coverage of Bugworks Research linked yet.
L Litmus · by Lapaas
Got an idea like this one? Validate it with the same 9-block framework, free.
Start Free ValidationFAQs on Bugworks Research
Who founded Bugworks Research?
Bugworks Research was founded by Anand Anandkumar, Santanu Datta, Balasubramanian V in 2014.
How much funding has Bugworks Research raised?
Bugworks Research has raised $34.5 Mn across 3 tracked funding round(s), most recently on 2022-02-09. Figures are compiled from cited public sources.
Who are the investors in Bugworks Research?
Investors in Bugworks Research include Lightrock India, 3one4 Capital, Acquipharma Holdings, Featherlite Group, Global Brain Corporation, I.M Holdings, Jim O'Neill, Kiran Mazumdar-Shaw.
What does Bugworks Research do?
Bugworks Research Inc. (Bugworks) is a clinical-stage biopharmaceutical company that is developing novel multi-target therapeutic assets in the anti-infectives and oncology areas by integrating the latest innovations in computational biology, pharmacology, structural-biology, and medicinal chemistry. BWC0977 is currently in a Phase I clinical trial and…
Where is Bugworks Research headquartered?
Bugworks Research is headquartered in Bengaluru, Karnataka, India.
What is Bugworks Research's business model?
Bugworks Research's core value proposition centers on Novel broad-spectrum antibiotic against drug-resistant superbugs (BWC0977), Efflux-pump avoidance platform (ELUDE) reduces resistance risk, Dual mechanism of action lowers resistance development, Pipeline extends into immuno-oncology.
How does Bugworks Research make money?
Bugworks Research's cited revenue streams include Milestone-based partnership funding from GARDP, Non-dilutive government/foundation grant funding, Future product sales/licensing revenue in retained commercialization territories.